IMAB - I-Mab
After hours:
| Previous Close | 2.9900 |
| Open | 3.0900 |
| Bid | 3.0600 x 1400 |
| Ask | 0.0000 x 900 |
| Day's Range | 2.9600 - 3.1200 |
| 52 Week Range | 2.7300 - 12.7590 |
| Volume | |
| Avg. Volume | 357,900 |
| Market Cap | 259.497M |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.4800 |
| Earnings Date | Aug 28, 2023 - Sept 01, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.50 |
- Thomson Reuters StreetEvents
Q4 2022 TRACON Pharmaceuticals Inc Earnings Call
Q4 2022 TRACON Pharmaceuticals Inc Earnings Call
Simply Wall St.We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Simply Wall St.
Shareholders in I-Mab (NASDAQ:IMAB) are in the red if they invested a year ago
It is doubtless a positive to see that the I-Mab ( NASDAQ:IMAB ) share price has gained some 83% in the last three...
- Simply Wall St.
Positive week for I-Mab (NASDAQ:IMAB) institutional investors who lost 91% over the past year
To get a sense of who is truly in control of I-Mab ( NASDAQ:IMAB ), it is important to understand the ownership...
- Simply Wall St.
I-Mab First Half 2022 Earnings: Misses Expectations
I-Mab ( NASDAQ:IMAB ) First Half 2022 Results Key Financial Results Revenue: CN¥51.9m (up 192% from 1H 2021). Net loss...
- Simply Wall St.
What You Need To Know About The I-Mab (NASDAQ:IMAB) Analyst Downgrade Today
Today is shaping up negative for I-Mab ( NASDAQ:IMAB ) shareholders, with the analysts delivering a substantial...
ZacksI-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal
I-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.